U.S. Markets open in 2 hrs 57 mins

Novo Nordisk to move forward with once-weekly diabetes shot, Bloomberg says

Novo Nordisk (NVO) is considering moving ahead with development of a once-weekly version of its Victoza daily diabetes shot, Bloomberg reports. A long-acting version of Victoza or the experimental semaglutide would challenge Bydureon, the once-weekly version of Byetta from Amylin (AMLN).